Medicina de Emergências
Estudo randomizado | Tratamento precoce da Covid-19 com sotrovimabe (anticorpo neutralizante do SARS-CoV-2) está associado a risco reduzido de internação.
28 Out, 2021 | 16:18h
Comentário no Twitter
In this phase 3 trial, sotrovimab or placebo was administered to outpatients within 5 days after the onset of #COVID19 symptoms. Patients receiving sotrovimab had a lower incidence of hospitalization for any reason. #IDTwitter https://t.co/4VcgoK3xac pic.twitter.com/W82v3jNRmB
— NEJM (@NEJM) October 27, 2021
Revisão sistemática | Antibióticos para o tratamento de COVID-19 – “Temos certeza de que o risco de morte em pacientes internados com COVID-19 não é reduzido pelo tratamento com azitromicina depois de 28 dias.”
26 Out, 2021 | 11:38hAntibiotics for the treatment of COVID‐19 – Cochrane Library
Comentário no Twitter
JUST PUBLISHED – Are #antibiotics an effective treatment for #COVID19 & do they cause unwanted effects? https://t.co/EVHduxmtdD New Cochrane Review looked at evidence from 11 studies: ❌ antibiotic azithromycin is not an effective treatment, 🤔not enough research on other types.
— The Cochrane Library (@CochraneLibrary) October 22, 2021
Estudo de coorte | Superinfecção por pneumonia bacteriana em pacientes em ventilação mecânica devido a COVID-19 – “Superinfecção bacteriana dentro de 48 horas de intubação foi detectada em 21% dos pacientes.”
26 Out, 2021 | 11:30h
Comentário no Twitter
Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia
🔓 Open Access
🔗 https://t.co/MaCZkKrQdQ pic.twitter.com/sscICvqYjS— ATS Blue Journal (@ATSBlueEditor) October 19, 2021
Opinião | COVID ESTEROIDE-2: dobro de esteroide, dobro de diversão? – “Dexametasona na dose de 6 mg/dia isoladamente parece ser subótima para a maioria dos pacientes com pneumonia por COVID. Já na dose de 12 mg/dia parece fornecer uma imunomodulação de intensidade razoável.”
25 Out, 2021 | 13:08hCOVID STEROID-2: Double the steroid, double the fun? – PulmCrit
Comentário no Twitter
COVID-STEROID 2
🥈5% lower mortality with 12 mg dexamethasone (vs 6 mg) – which is *huge* – but p=0.09 😩
🥈RCTs with toci/bari show that 6 mg dex alone is suboptimal.
🥈If using dex monotherapy, 12 mg is now a sensible dose for sicker pts.
Fresh blog: https://t.co/oPz7vAYHGN pic.twitter.com/diDqqUxSTC— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) October 23, 2021
Revisão | Envolvimento cardíaco nas implicações de longo prazo da COVID-19.
25 Out, 2021 | 13:06hCardiac involvement in the long-term implications of COVID-19 – Nature Reviews Cardiology
Orientação provisória de 2021 para prestadores de serviços de saúde sobre suporte cardíaco básico e avançado em adultos, crianças e recém-nascidos com COVID-19 suspeita ou confirmada.
25 Out, 2021 | 13:00hComentário: CPR on a COVID Patient: Not a Moment to Waste Looking for PPE: Updated AHA guidance says resuscitation should not be delayed by mask availability – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter (fio – clique para saber mais)
(1/2) NEW! The AHA has published its 2021 interim CPR guidance for #HCPs who treat cardiac arrest patients with suspected or confirmed #COVID19. The paper in @CircOutcomes is an update to the 2020 Interim CPR Guidance: https://t.co/tuTwWkE0dL. pic.twitter.com/B1el7dCKJM
— AHA CPR & First Aid (@HeartCPR) October 13, 2021
Diretriz | Estratégias de transfusão de sangue no sangramento de adultos criticamente doentes.
25 Out, 2021 | 12:58h
Comentário no Twitter
Transfusion strategies in bleeding critically ill adults current evidence/research areas from @ESICM clinical practice guideline
🩸massive bleedings
🩸non‑massive bleedings
🩸tranexamic acid in traumatic/non‑traumatic hemorrhages
Open #FOAMcc on @yourICM
🖇️https://t.co/LtEzrLcaM5 pic.twitter.com/Po7eFYpdeW— Intens Care Med (@yourICM) October 22, 2021
Estudo randomizado | Em sobreviventes em coma de parada cardíaca fora do hospital, não houve diferença na mortalidade ou nos desfechos neurológicos com hipotermia terapêutica leve (temperatura-alvo de 34 °C) ou moderada (temperatura-alvo de 31 °C).
25 Out, 2021 | 12:57hEffect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Conteúdos relacionados:
Study commentary: a history of hypothermia for cardiac arrest, 2002-2021 (RIP).
Comentário no Twitter
therapeutic hypothermia after cardiac arrest is a nonbeneficial form of iatrogenesis that prolongs ICU length of stay (findings entirely consistent with TTM & TTM2). currently it should not be performed outside the context of an RCT. https://t.co/GZbpgHXWoD https://t.co/kRwRpLz6hV
— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) October 20, 2021
M-A | Em pacientes com bacteriemia por Staphylococcus aureus, a terapia combinada não reduz a mortalidade e está associada a riscos aumentados de eventos adversos.
25 Out, 2021 | 12:50hA custo-efetividade da cefazolina comparada com penicilinas antiestafilocócicas no tratamento da bacteriemia por Staphylococcus aureus sensível à meticilina.
25 Out, 2021 | 12:48hConteúdos relacionados:
Meta-Analysis: Cefazolin vs. Antistaphylococcal Penicillins for MSSA Bacteremia
Comentários no Twitter
While Cefazolin and anti-staphylococcal penicillins (ASPs), such as nafcillin, are the preferred treatments for MSSA bacteremia it looks more and more like Cefazolin is really the preferred approach. https://t.co/6FVVEWMxBY
— Daniel Griffin MD PhD (@DanielGriffinMD) October 8, 2021
New in OFID: The use of cefazolin is a cost-effective strategy for the treatment of methicillin-sensitive S. aureus bacteremia and, when clinically appropriate, results in health care cost-savings.
📄: https://t.co/lRfsZdMjLJ#IDSAJournals @PaulSaxMD @DrJLi @ElMylonakis pic.twitter.com/hhzik4ppUW
— IDSA (@IDSAInfo) October 8, 2021